Alzheimer’s Drug Market, By Drug (Donepezil, Memantine, Galantamine, Rivastigmine, Donanemab and Gantenerumab), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and E-Commerce), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI488622 | Publish Date: August 2023 | No. of Pages: 168

Alzheimers Drug Market Overview

Alzheimer's disease is one of the most common neurodegenerative diseases, and it's linked to a longer life expectancy around the world. As a key symptom of dementia, the patient experiences a variety of behavioral changes, which worsen as the disease progresses. It primarily affects adults in the 65 age bracket. There is currently no pharmacological treatment for Alzheimer's disease, however available medications can help to reduce symptoms and the severity of the condition. Despite the fact that many companies have invested in the development of new Alzheimer's disease drugs, only a few molecules have shown a consistent improvement in patient condition, and many of those investigational candidates failed to provide significant improvement in patient condition during phase three clinical trials. The Global Alzheimer’s Drug Market accounted for US$ 3.79 billion in 2020 and is estimated to be US$ 8.86 billion by 2030 and is anticipated to register a CAGR of 9.0%.

COVID-19 Impact Analysis:

The emergence of the COVID-19 pandemic impacted the Alzheimer's drugs market, as diagnostic and therapeutic procedures around the world were impacted as patients visits hospitals and diagnostic centers less due to lockdown restrictions imposed by various governments around the world. Furthermore, several studies have shown that COVID-19 has a detrimental influence on Alzheimer's patients, which is predicted to have an impact on the market being examined. For example, in the study "Alzheimer's and Parkinson's disorders predict distinct COVID-19 outcomes, a UK Biobank study," released in November 2020, it was discovered that dementia patients have the highest risk of COVID-19 mortality. However, with continued vaccines and fewer occurrences of COVID-19, the market under consideration is projected to recover.

Alzheimers Drug Market Dynamics

Increasing use of biomarkers in Alzheimer's diagnosis and drug development

The increasing use of biomarkers in Alzheimer's diagnosis and drug development, as well as the rising prevalence of Alzheimer's disease around the world, are the primary factors driving the market for Alzheimer's disease diagnostics and therapies. According to the World Health Organization's September 2021 report, around 55 million people worldwide suffer from dementia, with nearly 10 million cases recorded each year. According to the same source, Alzheimer's disease is the most common kind of dementia, accounting for 60-70 percent of all dementia cases. Due to rising prevalence of Alzheimer's disease around the world, governments and non-governmental organizations are spending extensively in the development of diagnostics and therapies for the condition, which could boost market growth.

Increase in the incidence of various ailments and lifestyle choices

Diabetes, obesity, heart disease, and high blood pressure (BP), when combined with sedentary lifestyles, poor eating habits, and smoking, are known to enhance the risk of acquiring Alzheimer's disease. One of the primary reasons driving market expansion is an increase in the incidence of various ailments and lifestyle choices among the general public, together with the growing elderly population. Furthermore, the top pharmaceutical companies are concentrating on the development of medications that prevent the disease and provide long-term cognitive gains. The expansion of telehealth services and the growing popularity of online pharmacies are also contributing to market growth. In remote areas, these systems have enabled illness detection and treatment delivery.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Alzheimers Drug Market Segmentation

 

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The Global Alzheimer’s Drug Market is segmented based on drug, distribution channel and region.

On the basis of drug, the Global Alzheimer’s Drug Market is segmented into donepezil, memantine, galantamine, rivastigmine, donanemab and gantenerumab. Based on distribution channel, the target market is classified into hospital pharmacies, retail pharmacies and e-commerce.

Regional Insights:

The Global Alzheimer’s Drug Market accounted for US$ 3.79 billion in 2020 and is estimated to be US$ 8.86 billion by 2030 and is anticipated to register a CAGR of 9.0%.  On region the Global Alzheimer’s Drug Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America market for Alzheimer's drug is expected to grow significantly during the forecast period. Strong research and development landscape in the region, as well as the availability of well-established and superior healthcare infrastructure in the region, are some of the main drivers for the global Alzheimer's drugs market development in North America. Furthermore, factors such as the presence of a large number of players in the regional pharmaceutical industry, rising Alzheimer's disease cases in the region, and rising Alzheimer's disease awareness in the region are likely to drive growth in the global Alzheimer's drugs market in North America in the coming years. Moreover, In North America United States is expected to hold a major market share during the forecast period. This is due to high prevalence of Alzheimer’s disease, new product launches, growing geriatric population, and presence of well-equipped healthcare infrastructure for Alzheimer’s diagnostics and treatment. For instance, Approximately 6.2 million people of age 65 years and more are suffering with Alzheimer’s-related dementia and is expected to increase by 13.8% by 2060, according to Alzheimer’s Association March 2021. Moreover, death rate increased due to Alzheimer by 16% during the COVID-19 pandemic.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Drug- Donepezil, Memantine, Galantamine, Rivastigmine, Donanemab and Gantenerumab

By Distribution Channel– Hospital Pharmacies, Retail Pharmacies and E-Commerce

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Global Alzheimer’s Drug Market report based on drug, distribution channel, and region.

 

Global Alzheimer’s Drug Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Alzheimers Drug Market Key Players

 

The key players operating the Global Alzheimer’s Drug Market includes  Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. For instance, in November 2021, Brigham and Women’s Hospital in Boston, Unites States, came forward for starting clinical trial to test the safety and efficacy of new nasal vaccine for Alzheimer’s disease.

Drugs in Pipeline:

Drug Name

Description

Donanemab

Eli Lilly and Company has submitted the drug for an approval and if all goes according to the plan at FDA, company is aiming to launch the drug towards the end of year 2022.

Gantenerumab

Roche is finally launching drug in the year 2022. Sales of this drug is estimated to be $ 2.5 billion by 2026 which as same mechanism as Lilly’s anti-amyloid beta monoclonal antibody named donanemab.

Alzheimers Drug Market Company Profile

  • Abbvie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca PLC
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Daiichi Sankyo Company Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Ono Pharmaceutical Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Teva Pharmaceutical Industries Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

Alzheimers Drug Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Alzheimer’s Drug Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drugs
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Alzheimer’s Drug Market , By Drugs, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Donepezil
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Rivastigmine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Galantamine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Memantine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Donanemab
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
 

 

    • Gantenerumab
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  2. Global Alzheimer’s Drug Market By Distribution Channel, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends.
  • Hospital Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  • Retail Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  • E-Commerce
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  1. Global Alzheimer’s Drug Market , By Region, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn)By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
    • U.S.
    • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn)By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn)By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn)By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
    • Brazil
    • Mexico
    • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn)By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East
  2. Competitive Landscape
          • Heat Map Analysis
          • Market Presence and Specificity Analysis
  3. Company Profiles
  • Abbvie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca PLC
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Daiichi Sankyo Company Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Ono Pharmaceutical Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Teva Pharmaceutical Industries Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
          • Future Impact
          • About Us
          • Contact

FAQs

The global Alzheimer’s Drug market is segmented based on drug, distribution channel and region.

The increasing use of biomarkers in Alzheimer's diagnosis and drug development, as well as the rising prevalence of Alzheimer's disease around the world, are the primary factors driving the market for Alzheimer's disease diagnostics and therapies.

North America market for Alzheimer's drug is expected to grow significantly during the forecast period. Strong research and development landscape in the region, as well as the availability of well-established and superior healthcare infrastructure in the region, are some of the main drivers for the global Alzheimer's drugs market development in North America.

The key players operating the Global Alzheimer’s Drug Market includes Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.